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Abstract: Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of 
carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or 
impaired glucose tolerance. There is currently no evidence that AGIs are beneﬁ  cial to prevent 
or delay mortality or micro- or macrovascular complications in type 2 diabetes. Its beneﬁ  cial 
effects on glycated hemoglobin are comparable to metformin or thiazolidinediones, and probably 
slightly inferior to sulphonylurea. In view of the total body of evidence metformin seems to be 
superior to AGIs. More long-term studies are needed to study the effects of AGIs compared to 
other drugs. For patient with impaired glucose tolerance AGIs may prevent, delay or mask the 
occurrence of type 2 diabetes. A possible beneﬁ  cial effect on cardiovascular events should be 
conﬁ  rmed in new studies.
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Introduction
Type 2 diabetes (DM2) and associated cardiovascular diseases and cancer are an increasing 
problem around the globe, especially in the developed world (Beaglehole and Yach 2003). 
Currently, in the Netherlands the prevalence of DM2 is approximately 3.5% and this number 
is expected to increase by at least 32% in the next decades. This is due to the changing 
demographic characteristics (more elderly people), increasing problem of overweight and 
the improved and early detection of patients with DM2 (Baan and Poos 2007).
The diagnosis of DM2 is not clear-cut, but merely the result of an arbitrarily 
chosen point somewhere between the absence of insulin resistance and normal insulin 
secretion, and advanced peripheral insulin resistance and absence of insulin production. 
Therefore, the optimal moment to start treatment is not unequivocal. Speciﬁ  c criteria 
have been deﬁ  ned for those people who have raised post-prandial and/or fasting 
blood glucose, but who do not meet the criteria for DM2. This condition is referred 
to as ‘impaired glucose tolerance’ (IGT) when post-prandial blood glucose levels 
are elevated, and ‘impaired fasting blood glucose’ (IFBG) in case of elevated fasting 
blood glucose (criteria: Table 1).
In this paper, the current evidence is reviewed for the use of AGIs as initial treatment 
for patients with DM2, or as treatment for patients with IGT and/or IFBG.
Alpha-glucosidase inhibitors for treatment 
of type 2 diabetes mellitus
Diet and exercise is the ﬁ  rst step in the treatment of DM2. But if these measures alone fail 
to sufﬁ  ciently control blood glucose levels, starting oral drug therapy is recommended 
(Rutten et al 2006). To date, 6 classes of oral antihyperglycemic drugs are available: 
biguanides (metformin), sulphonylurea (eg, tolbutamide), glinidines (eg, repaglinide), 
thiazolidinediones (eg, pioglitazone), dipeptidyl peptidase IV inhibitors (eg, sitagliptin) 
and alpha-glucosidase inhibitors (AGIs; eg, acarbose) (Nathan 2007).Vascular Health and Risk Management 2008:4(6) 1190
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AGIs reversibly inhibit a number of alpha-glucosidase 
enzymes (eg, maltase), consequently delaying the absorption 
of sugars from the gut (Campbell et al 1996). In a recent study 
among healthy subjects it was suggested that the therapeutic 
effects of AGIs are not only based on a delayed digestion 
of complex carbohydrates, but also on metabolic effects 
of colonic starch fermentation (Wachters-Hagedoorn et al 
2007). Acarbose (Glucobay®) is the most widely prescribed 
AGI. The other AGIs are miglitol (Glyset®) and voglibose 
(Volix®, Basen®). AGIs might be a reasonable option as 
ﬁ  rst-line drug in the treatment of patients with DM2 as it 
speciﬁ  cally targets postprandial hyperglycemia, a possible 
independent risk factor for cardiovascular complications 
(Ceriello 2005). Although rare cases of hepatic injury were 
described, AGIs are expected to cause no hypoglycemic 
events or other life-threatening events, even at overdoses, 
and cause no weight gain (Chiasson et al 2003).
Effectiveness of AGIs in DM2: results
of a Cochrane Review
A Cochrane systematic literature review and meta-analysis 
investigated the effects of AGIs versus placebo (or any other 
intervention) with respect to mortality and (diabetes-related) 
morbidity, glycemic control, plasma lipids, insulin levels and 
body weight and side effects (Van de Laar et al 2005). In total, 
41 studies were included (30 acarbose, 7 miglitol, 1 voglibose, 
3 combinations). There was no evidence for an effect on 
mortality or morbidity. The other outcomes for acarbose and 
miglitol compared to placebo and sulphonylurea are listed 
in Table 2. Compared with placebo, AGIs had a beneﬁ  cial 
effect on glycated hemoglobin (GHb) (acarbose –0.8%, 95% 
CI 0.6–0.9; miglitol –0.7%, 95% CI 0.4–0.9), fasting and 
postload blood glucose and insulin levels. None of the AGIs 
had an effect on plasma lipids. Body mass index decreased by 
0.2 kg/m2 (95% CI 0.1–0.3), compared to placebo, although a 
similar meta-analysis for body-weight did not reach statistical 
signiﬁ  cance (decrease 0.13 kg; 95% CI –0.20 to 0.46). When 
compared with sulfonylurea, AGIs showed inferior glycemic 
control, but more decrease of fasting and postload insulin 
levels. Side effects of AGIs treatment were predominantly 
gastro-intestinal. When the dose exceeded 50 mg tid, the 
side effects increased, the blood post-load glucose levels 
showed more decrease, but the beneﬁ  cial effect on GHb did 
not increase. Although this effect is probably due to lower 
compliance in the higher dosage ranges, the conclusion that 
there is no need for dosages higher than 50 mg acarbose tid 
seems justiﬁ  ed. Too few comparisons with metformin were 
available to make a fair judgment. The seven available studies 
for miglitol are suggestive for comparable effects to acarbose. 
For voglibose only one study was found.
Place of AGIs in current therapeutic 
strategies A comparison with the other 
oral blood glucose lowering drugs
In 2006, the American Diabetes Association and European 
Association for the Study of Diabetes together published a 
‘consensus statement’ on the management of hyperglycemia. 
For all patients, metformin in combination with a lifestyle 
Table 1 Current deﬁ  nitions for diabetes mellitus, impaired glucose tolerance and impaired fasting blood glucose
WHO 2006 ADA 2007 Rutten et al 2006
Diabetes mellitus FPG   7.0
or
2HPG   11.1
Symptoms of diabetesa 
plus CPG   11.1
or
FPG   7.0 
or
2HPG   11.1b
Symptoms of diabetesa 
plus CPG   11.1 
or
FPG   7.0 on two 
occasions
Impaired glucose 
tolerance
FPG   7.0
and
2HPG 7.8–11.0
2HPG 7.8–11.0c No deﬁ  nition
Impaired fasting 
blood glucose
FPG 6.1–6.9 
and (if measured) 
2HPG   7.8
FPG 5.6–6.9c FPG   6.1 and  6.9c
Notes: All values are venous plasma glucose concentrations (mmol/L).
2HPG, 2 hours plasma glucose, glucose concentration 2 hours after ingestion of 75 g glucose; CPG, casual plasma glucose, casual is deﬁ  ned as any time of day without regard 
to time since last meal; FPG, fasting plasma glucose, fasting is deﬁ  ned as no caloric intake for  8 hours.
aThe classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss.
bThese criteria should be conﬁ  rmed by repeat testing ‘in the absence of unequivocal hyperglycemia’.
cExcluding patients fulﬁ  lling the criteria for type 2 diabetes.Vascular Health and Risk Management 2008:4(6) 1191
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intervention is advised, followed by the addition of either a 
thiazolidinedione (TZD), a sulphonylurea, or insulin when 
GHb remains  7%. AGIs are not included in the treatment 
algorithm, but is stated to be an “appropriate choice in 
selected patients” (Nathan et al 2006).
The guideline of the British National Institute for Clinical 
Excellence (2002) states that oral medication has to be 
initiated when lifestyle intervention alone fails. Metformin 
is therapy of ﬁ  rst choice and sulphonylurea should be given 
in case of contra-indications for metformin, or should be 
added when therapy with metformin alone fails. TZDs 
are recommended to be added in case of contraindications 
for metformin, or if the combination of metformin and 
sulphonylurea fails. AGIs may be considered as an alternative 
glucose-lowering therapy in people unable to use other oral 
drugs (National Institute for Clinical Excellence 2002).
The guidelines of the Dutch College of General 
Practitioners (DCGP) have changed recently. Acarbose 
used to be recommended as a drug for the treatment of 
DM2 when sulphonylurea and/or metformin failed, or in 
case of contra-indications for one of these drugs (Rutten 
et al 1999). In the current Dutch guideline, however, the 
only AGI that is available in the Netherlands, acarbose, is 
no longer recommended (Rutten et al 2006). Instead, TZDs 
are introduced in the guideline to be used when metformin 
fails in obese patients (BMI   27 kg/m2) with existing 
cardiovascular disease without an increased risk for heart 
failure. The low ranking of AGIs in all of these guidelines 
suggests that unequivocal evidence proving the superiority 
of the other oral drugs is available.
The case for metformin seems to be strong: metformin 
showed to reduce mortality and to have beneﬁ  cial effects 
on diabetes-related morbidity compared to sulphonylurea 
or insulin (Anon 1998a). Moreover, in meta-analyses 
metformin compared to placebo showed to decrease HbA1c 
by 0.9% (Johansen 1999) or 1.0% (Saenz et al 2005). The 
cases for sulphonylurea and TZDs are less strong. The 
beneﬁ  cial effects on microvascular complications that have 
been observed in patients using sulphonylurea or insulin, 
are most likely due to the effects of tight glycemic control 
and not due to direct effects of sulphonylurea (Anonymous 
1998b). Moreover, no beneﬁ  cial effects on diabetes related 
mortality and macrovascular morbidity has been found thus 
far for sulphonylurea. On the contrary, although the results 
of the University Group Diabetes Program suggesting an 
increased risk of cardiovascular morbidity with the use of 
tolbutamide were heavily criticized (Goldner et al 1971), 
sulphonylurea remained under the suspicion of unfavorable 
effects on cardiovascular disease up to now (Garratt et al 
1999; Simpson et al 2006). In addition, sulphonylureas carry 
the risk of inducing life threatening hypoglycemic events.
TZDs are becoming more popular; this is reﬂ  ected by the 
increased expenses of these drugs in the Netherlands: from 
2 million Euros in 2001 to almost 24 million Euros in 2005 
(Anon 2007). The PROACTIVE-study found a statistically 
signiﬁ  cant effect for pioglitazone compared to placebo in 
addition to regular treatment in obese patients with DM2 and 
known cardiovascular morbidity on a secondary composite 
endpoint consisting of total mortality, non-fatal myocardial 
infarction and cerebrovasular accident resulting in a NNT 
of 50 patients (treatment duration 3 years) (Dormandy et al 
2005). However, in a recent Cochrane systematic review with 
22 trials on the efﬁ  cacy of pioglitazone, it was concluded that 
thus far no convincing evidence for effects on mortality and 
morbidity exist and that the previously mentioned result of 
the PROACTIVE-study are hypotheses generating and need 
reconﬁ  rmation (Richter et al 2006). This precautious approach 
is underlined by results of a meta-analysis on another TZD, 
rosiglitazone, that showed an increased risk on myocardial 
infarctions and death from cardiovascular disease (Nissen 
and Wolski 2007). Moreover, it is important to realize that 
TZDs cause ﬂ  uid retention and are therefore contra-indicated 
in patients with or at increased risk for heart failure.
Compared with the evidence for the currently recom-
mended therapy (metformin, sulphonylurea, TZDs) as 
described above, the results of AGI-treatment, are less 
unfavorable than could be concluded from the low ranking 
of AGIs in the current guidelines. In indirect comparisons, 
the effect of AGIs on GHb is on average only 0.1% less 
compared to metformin (Saenz et al 2005) and 0.2 to 0.4% 
less compared to TZDs (Bolen et al 2007). Moreover, its 
effect on post-load glucose may be superior, although this is 
based on one comparison only (Hoffmann and Spengler 1997) 
and no data from meta-analyses are available. AGIs have a 
decreasing effect on the Body Mass Index, and the safety 
proﬁ  le is favorable as there is no evidence for dangerous side 
effects. Most important, there are clues that AGI may pre-
vent cardiovascular events in patients with impaired glucose 
tolerance in the STOP-NIDDM study (Chiasson et al 2003). 
However, this study is heavily debated and the results deserve 
re-conﬁ  rmation (Chiasson et al 2004; Kaiser and Sawicki 
2004). ‘Evidence’ from a study that reported beneﬁ  cial effects 
of acarbose on myocardial infarctions in patients with DM2 
has to be neglected because of publication bias, heterogeneity, 
detection bias and confounding (Hanefeld 2004; Van de Laar 
and Lucassen 2004). The results of three recently performed Vascular Health and Risk Management 2008:4(6) 1193
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trials are underway with mortality and morbidity endpoints 
in patients with abnormal glucose tolerance (Holman 2006; 
Kim 2006) and early diabetes (Tamita 2006).
The gastro-intestinal side effects of AGIs are clinically 
relevant and may affect compliance. In this respect, it is 
of interest that the Cochrane review found evidence that 
acarbose in a low dose (50 mg tid) has similar effects on GHb 
and less side effects compared to the double dose (100 mg tid) 
(Van de Laar et al 2005). Other possible disadvantages are 
the relatively higher costs compared to sulphonylurea and the 
need for a 3-times daily dosage schedule as opposed to TZDs 
or sulphonylurea that may be taken once or twice daily.
Altogether, AGIs appear to be a serious therapeutic option 
in the treatment of DM2 as they have a comparable effect on 
glycemic control compared to metformin, they pose no risk 
for harmful adverse events, they decrease body mass index, 
they possibly reduce the risk for cardiovascular disease and 
the side-effects may be reduced by administering a lower dose 
without inﬂ  uencing its effect on glycemic control. AGIs are 
not necessarily a drug in the form of a pill as it may also be 
given as ‘smart food’ or as a food supplement. For example, a 
soy-bean derived touchi extract, a traditional Chinese food in the 
form of a paste, has shown to have alpha-glucosidase inhibiting 
properties and reduce blood glucose levels (Fujita et al 2001).
AGIs in patients with impaired 
glucose tolerance or impaired 
fasting blood glucose
Two risk factors for the development of DM2 (and 
cardiovascular disease) are impaired glucose tolerance 
(IGT) and impaired fasting blood glucose (IFBG). Both are 
generally recognized as an expression of abnormal glucose 
homeostasis that is not (yet) severe enough to meet the cri-
teria for DM2. If one decides to treat these conditions, diet 
and exercise are an effective method to improve glucose 
tolerance and are recommended as ﬁ  rst choice treatment 
(Nathan et al 2007). With life-style modiﬁ  cations, a rela-
tive-risk reduction (RRR) in the progression to DM2 of 58% 
may be achieved (Tuomilehto et al 2001). Pharmacological 
treatment of IGT and IFBG may seem controversial, since 
it may implicate medicalization of the non-ill. According to 
a limited number of studies, especially drugs that improve 
insulin sensitivity may be useful in IGT and IFBG. Stud-
ies have been carried out with metformin (RRR of 31%, 
endpoint DM2) (Knowler et al 2002), and rosiglitazone 
(RRR of 60%, combined endpoint diabetes and death) 
(Gerstein et al 2006).
Effectiveness of AGIs in IGT or IFBG: 
results of a Cochrane Review
A Cochrane systematic literature review assessed the effects 
of monotherapy with AGIs (acarbose, miglitol or voglibose) 
in subjects with IGT or IFBG with respect to the development 
of DM2, cardiovascular disease, glycemic control, serum 
lipid proﬁ  le, blood pressure, body weight and side effects 
(Van de Laar et al 2006).
All randomized controlled trials of at least one-year 
duration, comparing AGI monotherapy with any other 
intervention were searched. In total, 5 trials were included 
(2360 participants). The results were dominated by one large 
scale study at low risk of bias (Chiasson et al 2002), the others 
were at high risk. Meta-analyses were not possible because of 
the limited data. Data from the ﬁ  rst-mentioned study suggest 
that acarbose decreases the occurrence of DM2 (RR 0.78, 95% 
CI 0.68–0.90, NNT = 10) and cardiovascular events (RR 0.46, 
95% CI 0.26–0.86, NNT = 50, based on 47 events). However, 
the study was not initially powered for the latter outcome and 
this ﬁ  nding needs conﬁ  rmation in more studies.
Place of AGIs in preventive strategies
In the Cochrane review, it was found that acarbose reduces 
the incidence of DM2 in patients with IGT. However, it 
remains unclear whether this should be seen as prevention, 
delay or masking of diabetes. Also, a preventive effect on 
combined cardiovascular endpoints on the occurrence of 
cardiovascular events was found, but this ﬁ  nding needs to 
be conﬁ  rmed because it was based on only 47 events in one 
study. Moreover, this study was not originally powered for 
that goal (Chiasson et al 2003). In the coming years, more 
data will be available from studies that have already been 
ﬁ  nished but yet unreported in full detail (Holman et al 2003; 
Nijpels 2005), and from studies that are currently ongoing 
(Kim 2006; Tamita 2006; Holman 2006). Thus far, lifestyle 
interventions are still much more effective in reducing the 
incidence of DM2 than AGIs (Knowler et al 2002; Ratner 
et al 2005; Tuomilehto et al 2001).
Nevertheless, regardless of available data, the question 
arises whether drug interventions in people with no disease 
and who do not even feel ill is desirable. General Practitioners 
are often confronted with the medical consequences of societal 
problems such as the massive adoption of sedentary lifestyles 
or loneliness and social isolation. But, just like a banker will 
talk money when confronted to problems, a doctor will most 
likely ‘talk medicine’ even when confronted with non-medical 
problems. This issue of medicalization, raised in the seventies 
of the twentieth century, is to date still actual and even more Vascular Health and Risk Management 2008:4(6) 1194
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complicated than before (Gupta 2003; Metzl and Herzig 
2007). In a focus group study with Welsh doctors and practice 
nurses unnecessary medicalization was a major concern with 
respect to preventive treatments for DM2 (Williams et al 
2004). No one will have the solution to the problem were 
the border should be between the medical domain and the 
responsibility of society as a whole, governments, schools 
and, last but not least, the individual himself. But asking the 
question in this philosophical and ethical issue is probably 
more important than any possible answer.
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